Mylan Poised To Launch Its First US Biosimilar, With A Stacked Pipeline Behind It
A biosimilar of Amgen's Neulasta appears on track for FDA approval by the June 4 action date, management said during an investor briefing that showcased Mylan's expansive biosimilar pipeline. Mid- to late-stage copies of products like Advair, Symbicort, Herceptin, Humira, Avastin, Rituxan, Eylea and Botox highlight the strategic direction Mylan moved in nearly a decade ago.
You may also be interested in...
Mylan has acquired commercial rights in Europe to Kyowa Hakko Kirin's biosimilar adalimumab, paving the way to an early market entry through the product, which could be approved in the second half of this year. But might there be a shift in the commercialization outlook for its partnered adalimumab with Biocon?
Mylan's revenue was down due to issues in the North American market, but the company is looking forward to development of new products to balance out losses in the future, including a newly announced Botox biosimilar.
Four health care systems representing 280 hospitals, with input from the US Department of Veterans Affairs, plan to make and sell their own generic drugs, focusing on those vitally needed by hospitals, with "appropriate" pricing.